Background: Rapid implementation of guidelines is a challenge in health care. Recognition programs are a proven strategy to drive hospital performance. This analysis reviews guideline-directed utilization of sodium glucose cotransporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) therapies in eligible patients with diabetes hospitalized with heart failure (HF) or stroke, comparing the period when the measure was used for quality feedback only or quality feedback and award.

Methods: Hospitals participating in American Heart Association’s (AHA) Get With The Guidelines® (GWTG)-Stroke and GWTG-HF document guideline adherence, including appropriate prescribing of SGLT-2 or GLP-1 in patients with type 2 diabetes prior to discharge. AHA established Target: Type 2 Diabetes (TT2D) to recognize guideline adherence for diabetes and cardiovascular disease.

Results: While hospitals have been able to review performance of appropriate SGLT-2 or GLP-1 prescribing since TT2D launched, this measure was not part of award eligibility for the first 2 years of the program.

graphic
View largeDownload slide

Conclusion: These findings show improvement from when the measure was used for quality feedback alone compared to use for recognition. Despite improvement, there remain significant opportunities to improve diabetes care and outcomes for patients hospitalized with diabetes along with HF or stroke.

Disclosure

G.C. Fonarow: None. R.M. Sednew: None. K. Overton: None. B. Pressley: None. M. Congdon: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.